Biofrontera Inc. (BFRIW) Financial Statements (2026 and earlier)

Company Profile

Business Address 120 PRESIDENTIAL WAY,
WOBURN, MA 01801
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,4015,9051,34327,75624,545
Cash and cash equivalent6,3925,9051,34317,20824,545
Short-term investments9  10,548 
Restricted cash and investments     47
Receivables4,700(200)(200)3,5588,629
Inventory, net of allowances, customer advances and progress billings1,4266,64610,9087,1684,458
Inventory1,4266,64610,9087,1684,458
Prepaid expense 1,705 305439824
Asset, held-for-sale, not part of disposal group  2,300   
Other undisclosed current assets3,8516,04910,7194,2197,918
Total current assets:18,08320,70023,07543,14046,421
Noncurrent Assets
Inventory, Noncurrent3,729    
Operating lease, right-of-use asset1,5849031,6121,375 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization2,15880134204267
Long-term investments and receivables    2,8132,813
Due from related parties✕✕✕✕2,8132,813
Intangible asset, including goodwill, after accumulated amortization2,650352,6293,0323,450
Intangible asset, excluding goodwill, after accumulated amortization2,650352,6293,0323,450
Restricted cash and investments200200200200150
Other undisclosed noncurrent assets160183282120118
Total noncurrent assets:10,4811,4014,8577,7446,798
TOTAL ASSETS:28,56422,10127,93250,88453,219
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,4304,2734,48712,14210,312
Accounts payable    1,278658
Accrued liabilities4,4304,2734,48710,8649,654
Debt   3,904  
Business combination, contingent consideration, liability    6,942 
Due to related parties✕✕✕✕1,312282
Other undisclosed current liabilities7,4657,7489,6974983,242
Total current liabilities:11,89512,02118,08820,89413,836
Noncurrent Liabilities
Liabilities, other than long-term debt1,2492998413,2695,649
Other liabilities92337215,649
Operating lease, liability1,240276804848 
Business combination, contingent consideration, liability    2,400 
Other undisclosed noncurrent liabilities4,9405,3484,2102,84322,396
Total noncurrent liabilities:6,1895,6475,0516,11228,045
Total liabilities:18,08417,66823,13927,00641,881
Equity
Equity, attributable to parent10,4804,4334,79323,87811,338
Common stock12922717
Additional paid in capital138,413121,833104,441103,37090,200
Accumulated deficit(127,945)(117,409)(99,650)(79,519)(78,879)
Total equity:10,4804,4334,79323,87811,338
TOTAL LIABILITIES AND EQUITY:28,56422,10127,93250,88453,219

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues41,70537,32134,07128,67424,100
Gain on disposition of assets for financial service operations  987,219  
Cost of revenue (35,301) (100)(33)
Cost of product and service sold   (100)(33)
Other undisclosed gross profit     
Gross profit:41,7052,02034,07128,57424,067
Operating expenses(53,053)(19,230)(56,748)(47,255)(49,301)
Other undisclosed operating income   10033
Operating loss:(11,348)(17,210)(22,677)(18,581)(25,201)
Nonoperating income (expense)837(527)2,56017,973(12,456)
Investment income, nonoperating257(7,421)1,747 
Other nonoperating income (expense)388158(75) 689
Interest and debt expense  (316)(220)(195)(344)
Loss from continuing operations before equity method investments, income taxes:(10,511)(18,053)(20,337)(803)(38,001)
Other undisclosed income from continuing operations before income taxes  316220195344
Loss from continuing operations before income taxes:(10,511)(17,737)(20,117)(608)(37,657)
Income tax expense(25)(22)(14)(32)(56)
Loss from continuing operations:(10,536)(17,759)(20,131)(640)(37,713)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(37,713)
Net loss available to common stockholders, diluted:(10,536)(17,759)(20,131)(640)(37,713)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(10,536)(17,759)(20,131)(640)(37,713)
Comprehensive loss, net of tax, attributable to parent:(10,536)(17,759)(20,131)(640)(37,713)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: